2. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl 2013;(197):19–24.
4. Piña-Garza JE, Lagae L, Villanueva V, et al. Long-term effects of adjunctive perampanel on cognition in adolescents with partial seizures. Epilepsy Behav 2018;83:50–58.
5. Hussein Z, Gidal B, Yang H, et al. Pharmacokinetic, pharmacodynamic and cognitive effects of adjunctive perampanel in adolescents With inadequately controlled partial seizures (P1.255). Neurology 2015;84(14 Suppl):P1.255.
6. Meschede C, Witt JA, Rademacher M, von Wrede RD, Elger CE, Helmstaedter C. Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting. Seizure 2018;58:141–146.
7. Ahn SJ, Kim TJ, Cha KS, et al. Effects of perampanel on cognition and quantitative electroencephalography in patients with epilepsy. Epilepsy Behav 2021;115:107514.
8. Liguori C, Spanetta M, Izzi F, et al. Perampanel increases cortical EEG fast activity in child and adult patients affected by epilepsy: a quantitative EEG study. Clin EEG Neurosci 2020;Aug 7; [Epub].
https://doi.org/10.1177/1550059420947936.
9. Fries P. A mechanism for cognitive dynamics: neuronal communication through neuronal coherence. Trends Cogn Sci 2005;9:474–480.
10. Beltramini GC, Cendes F, Yasuda CL. The effects of antiepileptic drugs on cognitive functional magnetic resonance imaging. Quant Imaging Med Surg 2015;5:238–246.
13. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–545.
14. Devinsky O, Ronsaville D, Cox C, Witt E, Fedio P, Theodore WH. Interictal aggression in epilepsy: the Buss-Durkee Hostility Inventory. Epilepsia 1994;35:585–590.
15. Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. Appl Nurs Res 2000;13:209–213.
16. Kim H, Na DL. Normative data on the Korean version of the Boston Naming Test. J Clin Exp Neuropsychol 1999;21:127–133.
17. Fastenau PS, Denburg NL, Hufford BJ. Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test. Clin Neuropsychol 1999;13:30–47.
18. Kim JK, Kang Y. Normative study of the Korean-California Verbal Learning Test (K-CVLT). Clin Neuropsychol 1999;13:365–369.
19. Sumerall SW, Timmons PL, James AL, Ewing MJ, Oehlert ME. Expanded norms for the Controlled Oral Word Association Test. J Clin Psychol 1997;53:517–521.
20. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol 1955;19:393–394.
21. Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1–25.
23. Babiloni C, Ferri R, Binetti G, et al. Fronto-parietal coupling of brain rhythms in mild cognitive impairment: a multicentric EEG study. Brain Res Bull 2006;69:63–73.
24. Beran RG, Lewis JH, Nolte JL, Westwood AP. Use of total and free anticonvulsant serum levels in clinical practice. Clin Exp Neurol 1985;21:69–77.
25. Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008;17:572–575.
26. Patsalos PN, Zugman M, Lake C, James A, Ratnaraj N, Sander JW. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. Epilepsia 2017;58:1234–1243.
27. Franco V, Crema F, Iudice A, Zaccara G, Grillo E. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70:35–40.